All trans retinoic acid mediated kruppel like factor 5 during the prevention of post transplant vein stenosis
余咏潮,朱培培,王国坤,徐志云,唐昊
DOI: https://doi.org/10.3760/cma.j.cn421213-20220118-00053
2022-01-01
Abstract:Objective:To study the role and mechanism of all trans retinoic acid (ATRA) regulating Kruppel factor 5 (KLF5) in the prevention of stenosis after vein transplantation.Methods:New Zealand white rabbits (provided by the Animal Experimental Center of Naval Military Medical University) were randomly divided into two groups: model group (groups A, B, C for 2, 4 and 8 weeks, respectively), ATRA group (groups D, E, F for 2, 4 and 8 weeks respectively, nasal ATRA 10 mg/day) and blank control group (group G). The transplanted vein samples were obtained and tested by hematoxylin eosin staining and immunohistochemistry. The KLF5 overexpression cell model of human umbilical vein smooth muscle cells (SMCs) was established. The proliferation and migration of SMCs were determined by ATRA intervention, scratch test and cell proliferation test (CCK-8). Immunocoprecipitation confirmed the blocking effect of ATRA on KLF5 rara binding. The measurement data between the two groups were analyzed by two independent sample
t-test, the measurement data between multiple groups were processed by one-way ANOVA, and the comparison between the two groups was done by LSD-
t test.
Results:The diameter in groups A, B, C, D, E, F and G was (107.58±18.11), (144.65±26.1), (160.28±28.06), (78.42±9.00), (102.75±16.47), (117.47±38.06) and (35.73±6.04) μm respectively. The diameter in the modeling groups was significantly greater than in the blank control group (
t=5.81, 8.81, 10.08,
P<0.01), and that in the modeling groups was significantly greater than in the ATRA groups (
t=2.06, 2.96, 3.03,
P<0.05). The expression of Ki67 (3.07±0.64 at 2nd week, 3.67±0.81 at 4th week and 1.93±0.41 at 8th week) in the modeling groups was significantly higher than that in the blank control group (reference index 1) (
t=6.93, 9.37 and 4.16,
P<0.01), and also higher than that in the ATRA group (2.87±0.52 at 2nd week, 3.60±1.21 at 4th week and 2.1±0.24 at 8th week,
t=4.91, 6.66 and 2.14,
P<0.05). The expression of KLF5 in the experimental group (4.43±0.70 at 2nd week, 5.67±1.18 at 4th week and 3.03±0.98 at 8th week) was significantly higher than that in the control group (reference index 1) (
t=7.27, 9.09 and 3.83,
P<0.01). There was no significant difference in the expression of KLF5 between the modeling group and ATRA group (4.43±0.70 at 2nd week, 5.67±1.18 at 4th week and 3.03±0.98 at 8th week,
t=0.49, 0.17 and 0.42,
P>0.05). For the CCK-8 assay, the absorbance (
A) value in KLF5 group (1.54±0.20) was higher than that in the rest three groups (
t=5.62, 5.84, 8.31,
P<0.01), that in KLF5+ ATRA group (1.02±0.14) was higher than that in ARTA group (0.80±0.07,
t=2.47,
P<0.05), and that in control group (1.04±0.13) was higher than that in ATRA group (
t=2.70,
P<0.05). For the scratch test, the ratio of scratch distance before and after migration in KLF5 group was 0.098±0.006, 0.404±0.009 in control group, 0.597±0.014 in ATRA group, and 0.265±0.012 in KLF5+ ATRA group. The ratio of scratch distance before and after migration in ATRA group was higher than the rest three groups (
t=4.81, 6.12, 8.41,
P<0.01) and that in KLF5 group was lower than in the rest three groups (
t=-8.37, -10.16, -12.25,
P<0.01). Immunocoprecipitation showed that KLF5 rara could combine to form a complex. The
A values of ATRA electrophoresis at different concentrations were statistically analyzed. The
A values in ATRA 50 μmol/ml group (1.38±0.15) and 70 μmol/ml ARTA group (1.19±0.12) were significantly lower than those in other groups [control group (1.88±0.16), 10 μmol/ml ARTA group (1.81±0.10), 30 μmol/ml ARTA group (1.76±0.13),
t=-5.60, -5.10, -4.80, -7.10, -6.80, -6.40,
P<0.01]. It is suggested that a certain concentration of ATRA can block KLF5 rara binding.
Conclusion:ATRA can inhibit the proliferation and migration of SMCs by blocking the binding of klf5-rara, so as to prevent vascular stenosis after vein transplantation.